Clinical and Translational Allergy


The Clinical and Translation Allergy (CTA) has been lauched by EAACI in 2011 and it is EAACI's contribution to the most important way of publishing research - open access. With an impact factor of 4.232, CTA accepts scientific papers and reviews in the allergy field in both basic
and clinical research, and aims to provide a very rapid and fair peer-review process.
The co-editors in Chief, Jean Bousquet and Clive Grattan, aim to increase the impact of the journal by promoting excellent quality research but also
by promoting EAACI Junior Members as follows:
 
Discount for EAACI Junior Members when publishing
When publishing with CTA, EAACI Junior Members benefit from a 20% discount on the total manuscript fee. In addition EAACI will cover 50%
of the remaining costs of the publication.
 
JMA-CTA collaboration
The JMA Working Group is very pleased to announce a new collaboration with the Clinical and Translational Allergy (CTA) journal - the JMA-CTA Collaboration. CTA welcomes the active involvement of the younger members of the Academy. Find out more here.
 
To go to the journal's website, please click here.
Last updated 27 June 2019